Liposomal Product Characterization
Home / Solution / Liposomal Product Characterization
Please input your keywords ...
Or by Phone: 1-631-504-
BOC Sciences characterizes liposome drugs according to the FDA production and control (CMC) guidelines. We can test for physicochemical properties,
encapsulation efficiency, and in vitro drug release and stability, and other specifications.
Why Characterize Liposome Products?
Characterizing liposome products reinforces quality control, which can ensure reproducibility. Assessment of liposome key quality attributes (CQA), such
as physicochemical properties, composition, encapsulation efficiency and drug release from liposome preparations, and establishing drug product
specifications are all crucial for drug development.
Based on our comprehensive liposome platform, BOC Sciences uses a variety of technologies for liposome analysis to support drug development.
What Do We Do?
Determine particle size and polydispersity index (PDI)
The particle size and distribution of liposomes are important parameters affecting drug loading, which determines the drug pharmacokinetics and
pharmacodynamics in circulation and the stability of the liposome solution.
The measurement of liposome Zeta potential can provide insights into liposome stability, circulation time, protein interactions, granular cell
permeability, and biocompatibility. By circumventing surface charge correlation, the biological properties of liposomes can be improved.
Encapsulation efficiency is one of the important parameters for assessing a drug delivery system. Drug encapsulation efficiency can be determined by
the amount of drug contained in the liposome and comparing it with the total drug and liposome drug loading.
In Vitro Drug Release
Liposomal drug release kinetics is a prerequisite for establishing a correlation between in vitro and in vivo studies of liposome drugs. Our team has
adopted a series of